AbbVie News Center - News
3 days ago · AbbVie News Center - News. Latest news. November 11, 2024. AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia. November 07, 2024. Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day. October 31, 2024.
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
3 days ago · AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an ...
AbbVie’s disappointing schizophrenia drug trial bodes well for …
2 days ago · AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie ABBV said that its Phase 2 trial ...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
Nov 30, 2023 · The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials
3 days ago · AbbVie Inc. shares sank in early trading after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of ...
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30, 2024 · AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings,...
AbbVie to Acquire Landos Biopharma, Further Strengthening its ... - News
Mar 25, 2024 · AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases. Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and ...
AbbVie lifts 2024 profit forecast, shares hit record high
July 25 (Reuters) - AbbVie (ABBV.N) increased its profit forecast for 2024 on Thursday after reporting strong sales of immunology drugs and quarterly results that exceeded Wall Street...
AbbVie Buy Rating Affirmed Despite Emraclidine Setback, Driven …
2 days ago · AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology.
AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia ...
3 days ago · By Colin Kellaher. AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical ...